Beam Therapeutics and Bio Palette Announce Exclusive License Agreements for Base Editing Technologies
Bio Palette licenses base editing intellectual property to Beam Therapeutics...
The human genome is made up of billions of nucleobases, or “bases,” represented by the letters A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.
Starting with our founders and funders, we’re building a world-class team to develop precision genetic medicines through DNA and RNA base editing. Join us.
Beam seeks an experienced scientist to help us advance our hematology programs, including precision engineering of hematopoietic stem and progenitorRead More
We are looking for a highly motivated and creative Flow Cytometrist to help us establish Immunophenotyping and Bioanalytical core capabilitiesRead More
We are looking for an engaged and enthusiastic researcher with experience in viral delivery vector characterization to join our growingRead More
26 Landsdowne Street
Cambridge, MA 02139